Back To: Home : Featured Technology : High Throughput Screening

CLICK HERE FOR WHAT'S NEW IN:
 

Cell-based assay enables researchers to distinguish primary mitochondrial dysfunction from secondary cytotoxic events
October 2011
SHARING OPTIONS:

Promega Corp.
 
Promega has launched the Mitochondrial ToxGlo Assay, a cell-based assay that enables researchers to quickly profile large compound libraries or medicinal modifications for their effects on mitochondria by allowing them to distinguish primary mitochondrial dysfunction from secondary cytotoxic events in a single well via a sequential-addition, multiplexed assay chemistry. The Mitochondrial ToxGlo Assay is based on the differential measurement of biomarkers associated with changes in cell membrane integrity and cellular ATP levels during short xenobiotic exposure periods. The assay is easy to automate and can be scaled to meet throughput needs for 96- and 384-well plate formats.
 
Promega Corp.
(608) 274-4330
www.promega.com  

 

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.